New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue 2, 2006, Pages 61-63

  Sever, Peter ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

British Hypertension Society; Guidelines; Hypertension; NICE

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VALSARTAN;

AGE DISTRIBUTION; ALGORITHM; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL PROTOCOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ETHNOLOGY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH ECONOMICS; HUMAN; HYPERTENSION; INCIDENCE; MEDICAL SOCIETY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PUBLICATION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DIURETICS; GREAT BRITAIN; HUMANS; HYPERTENSION; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 33748650250     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.011     Document Type: Article

References (10)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23.
2. Wolf-Maier K, Cooper RS, Kramer H et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43(1):10-17. Epub 2003, Nov 24.
3. Williams B, Poulter NR, Brown MJ et al. BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328(7440):634-40.
4. National Institute for Health and Clinical Excellence (NICE) website - http://www.nice.org.uk/CGO34guidance
5. European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21(6):1011-53.
6. Chobanian AV, Bakris GL, Black HR et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC7 Report. Hypertension. 2003;42(6):1206-52. Epub 2003 Dec 1.
7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-97.
8. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
9. Verdecchia P, Reboldi G, Angeli F, et al. Adverse Prognostic significance of new diabetes in treated hypertensive subjects. 2004;43:963-69.
10. Julius S, Kjeldsen SE, Weber M, Brunner HR et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlopidine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-31.